# Keiichi Fujiwara

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/keiichi-fujiwara/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,049 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 61 |
| i10-index | 230 |
| Last Known Institution | Saitama International Medical Center |
| OpenAlex ID | https://openalex.org/A5025271372 |
| ORCID iD | https://orcid.org/0000-0002-7388-0243 |
| Works | 659 |

## Researcher papers

- [Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer](https://scholariq.org/papers/olaparib-plus-bevacizumab-as-first-line-maintenance-in-ovarian-cancer/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial](https://scholariq.org/papers/bevacizumab-and-paclitaxel-carboplatin-chemotherapy-and-secondary-cytoreduction/)
- [Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study](https://scholariq.org/papers/avelumab-alone-or-in-combination-with-chemotherapy-versus-chemotherapy-alone-in/)
- [A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)](https://scholariq.org/papers/a-randomized-phase-iii-trial-to-evaluate-rucaparib-monotherapy-as-maintenance/)
- [Identification of Epigenetic Aberrant Promoter Methylation in Serum DNA Is Useful for Early Detection of Lung Cancer](https://scholariq.org/papers/identification-of-epigenetic-aberrant-promoter-methylation-in-serum-dna-is/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Intraperitoneal and Appendiceal Malignancies](https://scholariq.org/topics/intraperitoneal-and-appendiceal-malignancies/)

## Researcher university

- [Saitama International Medical Center](https://scholariq.org/institutions/saitama-international-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.